性别差异在进入比较效果药物试验的阿片类药物使用障碍患者的人口统计学和临床特征方面。
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
机构信息
Department of Psychiatry and New York State Psychiatric Institute, Columbia University Medical Center, New York, New York.
College of Nursing, Washington State University, New York, New York.
出版信息
Am J Addict. 2018 Sep;27(6):465-470. doi: 10.1111/ajad.12784. Epub 2018 Aug 14.
Abstract
BACKGROUND & OBJECTIVES: We investigated gender differences in individuals with opioid use disorder (OUD) receiving inpatient services and entering a randomized controlled trial comparing extended-release naltrexone to buprenorphine.
METHODS
Participants (N = 570) provided demographic, substance use, and psychiatric information.
RESULTS
Women were significantly younger, more likely to identify as bisexual, live with a sexual partner, be financially dependent, and less likely employed. Women reported significantly greater psychiatric comorbidity and risk behaviors, shorter duration but similar age of onset of opioid use.
DISCUSSION/CONCLUSIONS: Findings underscore economic, psychiatric, and infection vulnerability among women with OUD.
SCIENTIFIC SIGNIFICANCE
Interventions targeting these disparities should be explored, as women may face complicated treatment initiation, retention, and recovery. (Am J Addict 2018;27:465-470).
摘要
背景与目的
我们调查了接受住院治疗并参加比较纳曲酮缓释片和丁丙诺啡的随机对照试验的阿片类药物使用障碍（OUD）患者的性别差异。
方法
参与者（N=570）提供了人口统计学、物质使用和精神疾病信息。
结果
女性明显更年轻，更可能认同双性恋，与性伴侣同居，经济上依赖他人，就业可能性较小。女性报告了更严重的精神共病和风险行为，阿片类药物使用的持续时间较短，但发病年龄相似。
讨论/结论：研究结果强调了 OUD 女性在经济、精神和感染方面的脆弱性。
科学意义
应探索针对这些差异的干预措施，因为女性可能在治疗开始、维持和康复方面面临复杂的情况。（美国成瘾杂志 2018 年；27:465-470）。
相似文献
1
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
Am J Addict. 2018 Sep;27(6):465-470. doi: 10.1111/ajad.12784. Epub 2018 Aug 14.
2
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
3
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
Am J Addict. 2018 Sep;27(6):471-476. doi: 10.1111/ajad.12763. Epub 2018 Jul 20.
4
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Am J Addict. 2020 Jul;29(4):313-322. doi: 10.1111/ajad.13024. Epub 2020 Apr 4.
5
Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder.
Am J Addict. 2020 Nov;29(6):536-542. doi: 10.1111/ajad.13059. Epub 2020 May 21.
6
Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence.
J Sex Med. 2012 Dec;9(12):3198-204. doi: 10.1111/j.1743-6109.2011.02219.x. Epub 2011 Mar 2.
7
Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Drug Alcohol Depend. 2018 Feb 1;183:111-117. doi: 10.1016/j.drugalcdep.2017.10.017. Epub 2017 Dec 2.
8
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Drug Alcohol Depend. 2019 Dec 1;205:107649. doi: 10.1016/j.drugalcdep.2019.107649. Epub 2019 Oct 21.
9
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206.
10
Comparison of opioid use disorder among male veterans and non-veterans: Disorder rates, socio-demographics, co-morbidities, and quality of life.
Am J Addict. 2019 Feb;28(2):92-100. doi: 10.1111/ajad.12861. Epub 2019 Jan 21.
引用本文的文献
1
Perspectives and experiences with sleep and recovery among women receiving buprenorphine for opioid use disorder.
PLOS Ment Health. 2025;2(4). doi: 10.1371/journal.pmen.0000250. Epub 2025 Apr 8.
2
Sex Differences in Opioid Misuse among Adults with Chronic Lower Back Pain: The Roles of Negative Affect and Related Transdiagnostic Factors.
J Subst Use. 2025 Feb 9. doi: 10.1080/14659891.2025.2461288.
3
Gender and Overdose Risk Factors Among Clients Entering Residential Treatment for Opioid Use.
Drug Alcohol Rev. 2025 Jul 7. doi: 10.1111/dar.70004.
4
Social Safety Net Programs: The Relationship With Drug Treatment Among Women.
Am J Prev Med. 2025 Jun 14;69(3):107948. doi: 10.1016/j.amepre.2025.107948.
5
A retrospective cohort study evaluating the association between opioid and alcohol-related emergency department presentations and the subsequent risk of hospitalization.
PLoS One. 2025 Jun 11;20(6):e0325083. doi: 10.1371/journal.pone.0325083. eCollection 2025.
6
The co-creation and evaluation of a recovery community center bundled model to build recovery capital through the promotion of reproductive health and justice.
Addict Res Theory. 2024;32(6):455-465. doi: 10.1080/16066359.2023.2292589. Epub 2023 Dec 13.
7
Outcome of Buprenorphine maintenance treatment among Indian females with opioid dependence: Report from a tertiary addiction treatment center.
Indian J Psychiatry. 2025 Mar;67(3):303-309. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_928_24. Epub 2025 Mar 14.
8
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.
BMC Prim Care. 2024 Oct 11;25(1):361. doi: 10.1186/s12875-024-02609-9.
9
Digital health interventions to support women with opioid use disorder: A scoping review.
Drug Alcohol Depend. 2024 Aug 1;261:111352. doi: 10.1016/j.drugalcdep.2024.111352. Epub 2024 Jun 2.
10
Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.
Drug Alcohol Depend Rep. 2024 Mar 13;11:100226. doi: 10.1016/j.dadr.2024.100226. eCollection 2024 Jun.
本文引用的文献
1
Suicide: A Silent Contributor to Opioid-Overdose Deaths.
N Engl J Med. 2018 Apr 26;378(17):1567-1569. doi: 10.1056/NEJMp1801417.
2
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14.
3
Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study.
Biol Sex Differ. 2015 Nov 10;6:21. doi: 10.1186/s13293-015-0038-6. eCollection 2015.
4
An alcohol, tobacco, and other drug use comparison of lesbian, bisexual, and heterosexual undergraduate women.
Subst Use Misuse. 2015 Feb;50(3):340-9. doi: 10.3109/10826084.2014.980954. Epub 2014 Dec 9.
5
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.
Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982.
6
Gender differences in the rates and correlates of HIV risk behaviors among drug abusers.
Subst Use Misuse. 2010 Dec;45(14):2444-69. doi: 10.3109/10826084.2010.490928. Epub 2010 Jun 10.
7
From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment.
J Psychoactive Drugs. 2008 Nov;Suppl 5:327-43. doi: 10.1080/02791072.2008.10400661.
Zotero 插件